Does it excite you to work with
in vivo pharmacology? and do you have experience with
translating science? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
Your new position
As a Senior Scientist, In Vivo Pharmacology
, you will join the Obesity Pharmacology team in our Translational Pharmacology department. Here, you will work at the forefront of discovery research, contributing directly to the advancement of novel therapies for obesity and related comorbidities such as type 2 diabetes (T2D), cardiovascular disease (CVD), and MAFLD/MASH.
Working in cross-functional project teams, the position spans in-house in vivo studies and external collaborations, with a strong focus on translational science bridging pre-clinical research and clinical development.
We Offer Exciting Responsibilities
- Define and drive in vivo pharmacology strategies in cross‑functional project teams
- Serve as Study Director for in‑house and CRO studies, including study design, execution, data interpretation, and reporting
- Plan and deliver mechanism-of-action studies to support target validation and candidate differentiation
- Develop and refine relevant pharmacology models to support project progression
- Act as a scientific expert in disease and target biology, contributing to high‑quality project decisions
- Communicate results clearly to stakeholders and contribute to high-quality documentation and publications
Your profile
You are motivated by science with purpose and have a genuine interest in obesity and related comorbidities. Collaboration comes naturally, and communication is clear across disciplines and organizational levels. You take ownership, thrive in a dynamic research environment, and are motivated by seeing your contributions move closer to patients.
Your Background
- PhD in pharmacology, biology or similar
- Preferably at least 2 years of postdoctoral experience
- FELASA ABD certification
- Experience with animal models relevant to obesity and related comorbidities e.g. T2D, MAFLD/MASH, CVD etc.
- Proficiency in statistical analysis and strong experience in data interpretation, reporting, and publication
Your new team
At Zealand Pharma, you will be part of a highly collaborative and ambitious research environment, where scientific excellence, accountability, and respect are core values. Our Discovery Research organization is focused on identifying novel drug targets and advancing them efficiently toward clinical development.
The Obesity Pharmacology team consists of three laboratory technicians and five scientists and works in strong collaboration with the Animal Unit and CNS & Inflammation pharmacology team within Translational Pharmacology. You will be given responsibility, trust, and the opportunity to influence projects with potential to improve patients’ lives.
Let’s bond and be bold
We have a unique culture characterized by strong engagement, excellent teamwork, and a shared commitment to innovation. Making bonds is at the core of everything we do: from discovering and developing novel peptide‑based medicines for patients, to collaborating with our partners and connecting with each other. We bond through curiosity and playfulness, allowing ourselves to challenge conventional thinking and drive future innovation.
Interested in bonding with us?
Then please apply no later than
May 24th, 2026, or as soon as possible. Applications will be reviewed on an ongoing basis. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.
For further information, please contact Head of Obesity Pharmacology, Pernille Christensen PChristensen@zealandpharma.com
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
